Cytek Biosciences
CTKB
5.43
+0.07
+1.31%
Cytek Biosciences
US · CTKB
#3522 by market cap
Listed 2021
5.43
+0.07
+1.31%
Live - 5344 symbols - heartbeat 17s ago
· 2026-10-09 19:30
Analyst consensus 3 analysts
Buy
Avg price target
6.00 +10.5%
Price target rangecurrent 5.43
Low5.00
Avg6.00
High7.50
Buy 33%
Hold 67%
Sell 0%
Recent ratings (15)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-08-06 | Piper Sandler | -- | BUY | 7.50 |
| 2026-08-06 | Morgan Stanley | -- | HOLD | 5.50 |
| 2026-08-05 | TD Cowen | -- | HOLD | 5.00 |
| 2026-05-13 | Stephens | -- | BUY | 4.75 |
| 2026-05-12 | Morgan Stanley | -- | HOLD | 5.50 |
| 2026-05-08 | Piper Sandler | -- | BUY | 7.50 |
| 2026-05-07 | TD Cowen | -- | HOLD | 5.00 |
| 2026-02-27 | Piper Sandler | -- | BUY | 7.50 |
| 2026-02-26 | TD Cowen | -- | HOLD | 5.00 |
| 2025-12-04 | Piper Sandler | -- | BUY | 7.50 |
| 2025-12-01 | Morgan Stanley | -- | HOLD | 6.00 |
| 2025-11-11 | Piper Sandler | -- | BUY | 7.50 |
| 2025-11-05 | TD Cowen | -- | HOLD | 4.00 |
| 2025-10-13 | TD Cowen | -- | HOLD | 4.00 |
| 2025-10-10 | TD Cowen | -- | HOLD | 4.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | After close | -- | -0.48% |
| 2026/Q1 | 2026-05-07 | After close | -- | -6.30% |
| 2025/Q4 | 2026-02-26 | After close | -- | +1.82% |
| 2025/Q3 | 2025-11-05 | After close | -- | +13.22% |
| 2025/Q2 | 2025-08-06 | After close | -- | +5.66% |
| 2025/Q1 | 2025-05-08 | After close | -- | -22.82% |
| 2024/Q4 | 2025-02-27 | After close | -- | -6.65% |
| 2024/Q3 | 2024-11-05 | After close | ±38.24% | +36.03% (in line) |
| 2024/Q2 | 2024-08-06 | After close | ±45.91% | -9.43% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±23.13% | -1.12% (in line) |
| 2023/Q4 | 2024-02-28 | After close | ±21.74% | -11.90% (in line) |
| 2023/Q3 | 2023-11-07 | After close | -- | +12.36% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-09 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Cytek Biosciences discussion 0 comments